Pierre Fabre Seeks EMEA Nod for Milnacipran in Fibromyalgia.

BioWorld International Correspondent

PARIS - Pierre Fabre Medicament SA filed a marketing approval application with the European Medicines Agency (EMEA) for milnacipran, a dual-reuptake inhibitor for the treatment of fibromyalgia syndrome (FMS).

The application follows the Castres, France-based company's presentation of positive results from a pivotal Phase III trial of the drug in Europe.

FMS is a chronic rheumatological disorder characterized by widespread musculoskeletal pain, tenderness, fatigue and sleep disorders, and also is associated with a variety of other symptoms, …